 "Sun Pharma")
India’s largest drug maker Sun Pharmaceutical Industries is readying to start trials on a few drugs that have emerged as potential treatment candidates for Covid-19. This includes an anti-coagulant and anti-inflammatory drug nafamostat and another plant-based dengue drug candidate that Sun Pharma was developing along with government research institutes.
The development comes at a time when several Indian companies are lining up testing of potential drug candidates on Covid-19 patients. Mumbai-based Glenmark, too, has started trials on favipiravir, an influenza drug that has shown some promise.
On Friday, Sun Pharma said it received the nod from the Drug Controller General of India (DCGI) to initiate a clinical trial with nafamostat mesilate on Covid-19 patients. These will be phase II trials on about
